18F-氟甲基胆碱PET/CT对寡转移前列腺癌SBRT前预后价值
回顾性分析40例≤4个异时性转移灶的前列腺癌患者,SBRT前接受18F-氟甲基胆碱PET/CT,测量转移灶数目及SUVmean、SUVmax、SUVpeak、MATV、总胆碱摄取病灶等参数。中位随访32.6个月,中位PFS为11.5个月;
要点
- SUVmean、SUVmax、SUVpeak及总胆碱摄取病灶对PFS无显著预测价值。
核心结论
- 胆碱高摄取转移灶数目是复发寡转移前列腺癌SBRT后进展的显著预后因素。
- MATV较大者进展风险呈趋势,但病灶水平18F-氟甲基胆碱摄取对进展无预后价值。
研究设计与样本
- 回顾性研究,纳入40例≤4个异时性转移灶并接受SBRT的寡转移前列腺癌患者。
- 在18F-氟甲基胆碱PET/CT上测量转移灶数目、SUVmean、SUVmax、SUVpeak、MATV和总胆碱摄取病灶,并用Lucy-Richardson迭代反卷积行部分容积校正。
主要发现
- 中位随访32.6个月(四分位距35.5个月),中位PFS为11.5个月(95%CI 8.4-14.6个月)。
- 无论是否行部分容积校正,SUV及总胆碱摄取病灶均未显著预测PFS。
临床怎么用
- SBRT前可依据18F-氟甲基胆碱PET/CT所示胆碱高摄取转移灶数目进行风险分层,多发病灶者预后较差。
- 病灶水平SUV不宜单独用于筛选SBRT获益人群,MATV的预后价值需进一步验证。
局限性
- 回顾性设计,样本量仅40例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To investigate the predictive value of [18F]-fluoromethylcholine positron emission tomography/computed tomography (PET/CT)-derived parameters on progression-free survival (PFS) in oligometastatic prostate cancer patients treated with stereotactic body radiation therapy (SBRT). METHODS AND MATERIALS: In [18F]-fluoromethylcholine PET/CT scans of 40 consecutive patients with ≤4 metachronous metastases treated with SBRT we retrospectively measured the number of metastases, standardized uptake values (SUVmean, SUVmax, SUVpeak), metabolically active tumor volume (MATV), and total lesion choline uptake. Partial-volume correction was applied using the iterative deconvolution Lucy-Richardson algorithm. RESULTS: Thirty-seven lymph node and 13 bone metastases were treated with SBRT. Thirty-three patients (82.5%) had 1 lesion, 4 (10%) had 2 lesions, and 3 (7.5%) had 3 lesions. After a median follow-up of 32.6 months (interquartile range, 35.5 months), the median PFS was 11.5 months (95% confidence interval 8.4-14.6 months). Having more than a single metastasis was a significant prognostic factor (hazard ratio 2.74; P = .03), and there was a trend in risk of progression for large MATV (hazard ratio 1.86; P = .10). No SUV or total lesion choline uptake was significantly predictive for PFS, regardless of partial-volume correction. All PET semiquantitative parameters were significantly correlated with each other (P ≤ .013). CONCLUSIONS: The number of choline-avid metastases was a significant prognostic factor for progression after [18F]-fluormethylcholine PET/CT-guided SBRT for recurrent oligometastatic prostate cancer, and there seemed to be a trend in risk of progression for patients with large MATVs. The lesional level of [18F]-fluoromethylcholine uptake was not prognostic for progression.
引用
- Cysouw M, Bouman-Wammes E, Hoekstra O, et al. Prognostic Value of [18F]-Fluoromethylcholine Positron Emission Tomography/Computed Tomography Before Stereotactic Body Radiation Therapy for Oligometastatic Prostate Cancer. Int J Radiat Oncol Biol Phys. 2018. PMID: 29559285. doi:10.1016/j.ijrobp.2018.02.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。